Skip to main content

Advertisement

SpringerLink
Log in

UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The uridine diphosphate glucuronosyltransferase (UGT) gene 1A1*6 polymorphism, which affects irinotecan metabolism, has been associated with improved survival in lymphoma patients treated with of carboplatin, dexamethasone, etoposide and irinotecan (CDE-11). This study assessed the efficacy of CDE-11 relative to the UGT1A1*6 polymorphism in 27 elderly patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for high-dose chemotherapy plus autologous stem cell transplantation. The 2-year survival rate after initial CDE-11 treatment was significantly higher in patients with than without UGT1A1*6 (57% vs. 5%). The most common grade 4 adverse event in patients with the UGT1A1*6 genotypes was neutropenia (88.9%), but there were no gastrointestinal adverse events or treatment-related deaths. Disease progression was the most frequent cause of death. CDE-11 was well tolerated and provided clinical benefit to elderly patients with relapsed or refractory diffuse large B-cell lymphoma. The response to CDE-11 likely correlated with UGT1A1*6 polymorphisms, but further prospective studies are warranted to optimize irinotecan-based chemotherapies relative to UGT1A1 polymorphism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, BoslyA MP, Nouvel C, Tilly H, Lederlin P, Sebban C, Brière J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:3025–3030

    CAS  PubMed  Google Scholar 

  2. Sarkozy C, Coiffier B (2013) Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res 19:1660–1669

    Article  CAS  PubMed  Google Scholar 

  3. Suzumiya J, Suzushima H, Maeda K, Okamura S, Utsunomiya A, Shibuya T, Tamura K; Kyushu Hematology Organization for Treatment Study Group (2004) Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol 79:266–270

    Article  Google Scholar 

  4. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182–2194

    CAS  PubMed  Google Scholar 

  5. Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PloS One 8:e58489

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255–1259

    Article  CAS  PubMed  Google Scholar 

  7. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244

    Article  CAS  PubMed  Google Scholar 

  8. Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H (2012) Is there diversity among UGT1A1 polymorphism in Japan. World J Gastrointest Oncol 4:170–175

    Article  PubMed Central  PubMed  Google Scholar 

  9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  Google Scholar 

  10. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604–610

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the patients and clinical staff for their participation in the study. The authors also acknowledge the Clinical Research Institute, Kyushu Medical Hospital, for editorial support.

Conflict of interest

The authors declare that they have no conflict of interest.

Author contributions

S.Y. contributed to the study design, data analysis, and manuscript preparation; K.T., K.K., M.K., K.T, S.K., A.K., M.T., and S.O. reviewed the manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-Ku, Fukuoka, 810-8563, Japan

    Satoshi Yamasaki, Kazuki Tanimoto, Kentarou Kohno, Masanori Kadowaki, Ken Takase, Seiji Kondo, Akira Kubota & Seiichi Okamura

  2. Department of Hematology/Oncology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

    Kazuki Tanimoto

  3. Department of Hematology, Saga Prefectural Hospital Koseikan, Saga, Japan

    Seiji Kondo

  4. Department of Pathology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

    Morishige Takeshita

Authors
  1. Satoshi Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuki Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kentarou Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Kadowaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken Takase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seiji Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akira Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Morishige Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seiichi Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Yamasaki.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamasaki, S., Tanimoto, K., Kohno, K. et al. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Ann Hematol 94, 65–69 (2015). https://doi.org/10.1007/s00277-014-2170-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2170-5

Keywords

Search

Navigation